Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

Published:2020-05 Issue:5 Volume:21 Page:710-722
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ledermann Jonathan A,Oza Amit M,Lorusso Domenica,Aghajanian Carol,Oaknin Ana,Dean Andrew,Colombo Nicoletta,Weberpals Johanne I,Clamp Andrew R,Scambia Giovanni,Leary Alexandra,Holloway Robert W,Gancedo Margarita Amenedo,Fong Peter C,Goh Jeffrey C,O'Malley David M,Armstrong Deborah K,Banerjee Susana,García-Donas Jesus,Swisher Elizabeth M,Cameron Terri,Maloney Lara,Goble Sandra,Coleman Robert L

Funder

Memorial Sloan Kettering Cancer Center

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Advances in the management of platinum-sensitive relapsed ovarian cancer;Bouberhan;J Clin Oncol,2019

2. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J Clin Oncol,2012

3. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer;Ledermann;N Engl J Med,2012

4. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer;Mirza;N Engl J Med,2016

5. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial;Coleman;Lancet Oncol,2017

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type;Frontiers in Oncology;2024-09-09

2. Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers;Cancers;2024-09-05

3. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

4. Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis;Taiwanese Journal of Obstetrics and Gynecology;2024-09

5. STEREOTACTIC BODY RADIOTHERAPY FOR OLIGOPROGRESSIVE OVARIAN CANCER PATIENTS TREATED DURING PARP INHIBITOR MAINTENANCE: EFFICACY AND ADVERSE EVENTS FROM THE EPIMETHEO RETROSPECTIVE STUDY;International Journal of Radiation Oncology*Biology*Physics;2024-09